Power of Al in Improving Early Diagnosis and Care for Alzheimer's Disease and Dementia

Artificial intelligence (AI) is transforming dementia research and care by detecting patterns in large, complex datasets, particularly through machine learning, that can help identify early biological changes, improve diagnostic accuracy across dementia types, and support precision medicine approaches tailored to a patient's genes, environment, and lifestyle.

Faster and More Accurate Diagnosis

Al is improving the analysis of brain imaging (i.e. MRI and PET scans) by identifying early biomarkers associated with Alzheimer's disease well before symptoms arise. These models can detect subtle brain atrophy and amyloid (plaque) growth, aiding in earlier and more accurate diagnosis. For example, machine learning tools can analyze brain waves during sleep and other factors as early indicators of cognitive decline. In 2024, the Food and Drug Administration (FDA) approved BrainSee to predict the likelihood of Alzheimer's progression based on a patient's MRI.

Expanding Access to Expert-Level Care

Al-driven tools can bring cognitive screening and neurological assessments to primary care settings and rural communities. Digital applications can evaluate memory, attention, and language abilities through simple tasks performed on tablets or smartphones, allowing earlier interventions even in underserved communities. An example is Linus Health' DCTClock Platform which has transformed the Clock Drawing Test with machine learning analysis of drawing behaviors to better detect nuances in cognitive performance and hence earlier detection.

Slowing Disease Progression

Al can analyze an individual's medical history and forecast potential health issues using population-wide data. For example, Al models have been used to assess a person's medical records, genetic information, and lifestyle factors to effectively predict the risk of developing Alzheimer's and track disease progression. These insights can be used to guide clinicians in recommending preventative strategies tailored to individual risk profiles.

Enhancing Patient Communication & Caregiver Support

Al-powered chatbots and virtual assistants are increasingly used to address common questions from patients and caregivers, provide medication and appointment reminders, support remote care, and even offer emotional support. These technologies also facilitate remote monitoring by collecting and analyzing data to better inform clinical decisions. By streamlining communication and care tasks, they can help reduce caregiver burden and enhance daily care routines.

Challenges and Considerations

As Al continues to show promise in supporting Alzheimer's care and research, it's essential to acknowledge the challenges and responsibilities that come with its integration into clinical practice. Ensuring ethical, equitable, and accurate use of Al will be critical to maximizing its benefits while safeguarding patient well-being.

Al As an Assistant, not a Replacement

Al should be viewed as a powerful assistant to clinicians—not a substitute for their expertise. Given the complexity of Alzheimer's disease, including its evolving symptoms and overlapping forms of dementia, human oversight remains essential. Physicians must continue to review Algenerated insights, validate them against clinical judgment, and lead in making final diagnoses and treatment decisions. Over-reliance on Al without proper validation could result in misdiagnoses or missed opportunities for intervention.

Minimizing Bias in Al Models

Al algorithms are only as good as the data they are trained on. If these models are developed using data that lacks diversity, they may not perform well across all populations, leading to disparities in diagnosis and care. To promote health equity, it is critical that Al systems be tested and validated on data representative of different racial, ethnic, gender, and socioeconomic groups. Addressing algorithmic bias must be a priority in the development and deployment of these tools.

Accuracy and Liability

Al systems can make mistakes, so continuous monitoring, validation, and improvement will be essential to ensure patient safety and effectiveness in clinical settings. Continuous monitoring, validation against real-world outcomes, and frequent updates are needed to ensure Al systems remain reliable over time. Regulatory bodies and healthcare organizations must establish clear standards and frameworks for evaluating Al performance in clinical practice.

Privacy and Data Security

Al applications often rely on large datasets, including sensitive personal health information. Ensuring robust privacy protections and secure data handling is crucial, especially as these systems are adopted more widely across healthcare settings. Clear guidelines around consent, data sharing, and transparency are vital to maintain trust among patients, families, and providers.

References

AlMansoori ME, Jemimah S, Abuhantash F, AlShehhi A. Predicting early Alzheimer's with blood biomarkers and clinical features [published correction appears in Sci Rep. 2024 Aug 30;14(1):20210.

Sima DM, Phan TV, Van Eyndhoven S, et al. Artificial Intelligence Assistive Software Tool for Automated Detection and Quantification of Amyloid-Related Imaging Abnormalities. JAMA Netw Open. 2024;7(2):e2355800.

Yin C, Imms P, Chowdhury NF, et al. Deep learning to quantify the pace of brain aging in relation to neurocognitive changes. Proc Natl Acad Sci U S A. 2025;122(10):e2413442122.

Brain Waves Measured During Sleep Predict Cognitive Impairment Years Before Symptoms Appear | Mass General Brigham Newsroom. 2025. Mar 4.

Veneziani I, Marra A, Formica C, et al. Applications of Artificial Intelligence in the Neuropsychological Assessment of Dementia: A Systematic Review. J Pers Med. 2024;14(1):113. Published 2024 Jan 19.

Souillard-Mandar W, Penney D, Schaible B, Pascual-Leone A, Au R, Davis R. DCTclock: Clinically-Interpretable and Automated Artificial Intelligence Analysis of Drawing Behavior for Capturing Cognition. Frontiers in Digital Health. Vol 3.2021.

Kale M, Wankhede N, Pawar R, et al. Al-driven innovations in Alzheimer's disease: Integrating early diagnosis, personalized treatment, and prognostic modelling. Ageing Res Rev. 2024;101:102497.

Qiu S, Miller MI, Joshi PS, et al. Multimodal deep learning for Alzheimer's disease dementia assessment. Nat Commun. 2022;13(1):3404. Published 2022 Jun 20.

Ruggiano N, Brown EL, Roberts L, et al. Chatbots to Support People With Dementia and Their Caregivers: Systematic Review of Functions and Quality. J Med Internet Res. 2021;23(6):e25006. Published 2021 Jun 3. doi:10.2196/25006

